Article Text

PDF
Takotsubo cardiomyopathy: pathophysiology and treatment
  1. Kristijonas Milinis1,
  2. Michael Fisher2
  1. 1Medical School, University of Liverpool, Liverpool, UK
  2. 2Royal Liverpool University Hospital, Institute for Cardiovascular and Medical Sciences, Liverpool, UK
  1. Correspondence to Dr Michael Fisher, Royal Liverpool University Hospital, Institute for Cardiovascular and Medical Sciences, Liverpool L7 8XP, UK; michael.fisher{at}rlbuht.nhs.uk

Abstract

Since it was first described 20 years ago in Japan, takotsubo cardiomyopathy has received considerable interest from the medical community around the world, particularly in recent years. Although takotsubo cardiomyopathy was originally described as a transient, stress-induced dysfunction of the left ventricular apex, other morphological subtypes have now been described. The pathogenesis of this disorder is likely to be catecholamine mediated myocyte damage and microvascular dysfunction; however, a number of possible alternative theories have been suggested. These include oxidative stress, transient coronary obstruction and oestrogen deficiency, the last explaining the high prevalence of takotsubo cardiomyopathy in women. The treatment remains largely supportive; however, a number of agents have been implicated in the acute stage and long term. Although most of the patients show complete recovery, there is a high risk of complications at the initial presentation requiring intense support.

  • Cardiology
  • cardiomyopathy

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.